REGN Net income
Net income at Regeneron Pharmaceuticals rose to $4.5B in fiscal 2025, from $4.4B in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 872589 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$4.5B
FY2024 $4.4B
HIGH$8.1B FY2021
LOW$4.0B FY2023
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $4.5B | +$92M |
| FY2024 | $4.4B | +$459M |
| FY2023 | $4.0B | $-385M |
| FY2022 | $4.3B | $-3.7B |
| FY2021 | $8.1B | — |
More SAME DATA, OTHER VIEWS
Net income across coverage → · REGN company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.